DCT platform to deliver stronger evidence of therapeutic efficacy and safety.
ObvioHealth announces the launch of ObvioGo, a decentralized clinical trial platform and mobile application.
ObvioGo's tech stack has been designed to capture and integrate multi-source data. The system incorporates digital instruments, real-world data, artificial intelligence, as well as integration with clinical systems via APIs and industry standard interfaces.
Read more about the new platform here.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.